Abstract
Background Spending on biological agents has risen dramatically due to the high cost of the drugs and the increased prevalence of spondyloarthritis. Objective To evaluate the annual cost per patient and cost for each biological drug for treating patients with spondyloarthritis from 2009 to 2016, and to calculate factors that affect treatment cost, such as optimizing therapies by monitoring drug serum levels, the use of biosimilar-TNF inhibitors, and official discounts or negotiated rebates in biologicals acquired by the pharmacy department. Method Retrospective, observational study in a Spanish tertiary hospital. Main outcome Annual cost per patient and per drug. Factors that influenced the costs and socio-demographic parameters and disease activity. Results A total of 129, 215, and 224 patients were treated in 2009, 2013, and 2016, respectively. The annual cost per patient decreased: EUR11,604 in 2009, EUR8513 in 2013, and EUR7464 in 2016. The introduction of new drugs drives economic competition, leading to total savings per drug, with discounts reaching 5.8, 12.4, 16.7, 17.7, 13.7, and 24.8% for original infliximab, etanercept, adalimumab, ertolizumab, golimumab, and secukinumab, respectively, while rebates for biosimilar infliximab reached 31.90% in 2016. The number of patients with optimized therapies reached 47.5% in 2016, which led to cost savings of EUR798,614, in addition to savings from official discounts and rebates of EUR252,706 and savings from optimized therapies of EUR545,908 in 2016. Conclusion The cost of biological treatments declined after official discounts, negotiated rebates, and optimized therapies, leading to a significant decrease in the annual cost per patient. The greatest contribution to economic savings in biological therapy according to our study was biological therapy optimization.
Similar content being viewed by others
References
Zochling J, Smith EUR. Seronegative spondyloarthritis. Best Pract Res Clin Rheumatol. 2010;24:747–56.
Hukuda S, Minami M, Saito T, Mitsui H, Matsui N, Komatsubara Y, et al. Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol. 2001;28:554–9.
Muñoz-Fernández S, de Miguel E, Cobo-Ibáñez T, Carmona L, Steiner M, Descalzo MA, et al. Early spondyloarthritis: results from the pilot registry ESPIDEP. Clin Exp Rheumatol. 2010;28:498–503.
Quintana G, Coral-Alvarado P. Economic impact of rheumatic diseases. Chall Rheumatol [Internet]. 2011. http://www.intechopen.com/books/challenges-in-rheumatology/economic-impact-of-rheumatic-diseases. Citado 5 marzo 2018.
Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol Hoboken NJ. 2016;68:282–98.
van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978–91.
Tanaka Y. Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal? Ann Rheum Dis. 2013;72(suppl 2):ii124–7.
Informe técnico ANTI-TNF-reumatología. infliximab_y_adalimumab.pdf [Internet]. http://sescam.castillalamancha.es/sites/sescam.castillalamancha.es/files/documentos/farmacia/infliximab_y_adalimumab.pdf. Cited 8 March 2018.
Plasencia C, Pascual-Salcedo D, García-Carazo S, Lojo L, Nuño L, Villalba A, et al. The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients. Arthritis Res Ther. 2013;15:R79.
Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70:47–53.
Ariza-Ariza R, Hernández-Cruz B, Navarro-Sarabia F. La versión española del BASDAI es fiable y se correlaciona con la actividad de la enfermedad. Rev Esp Reumatol. 2004;31:372–8.
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286–91.
Real Decreto Legislativo 3/2011, de 14 de noviembre, por el que se aprueba el texto refundido de la Ley de Contratos del Sector Público [Internet]. Noticias Jurídicas. http://noticias.juridicas.com/base_datos/Admin/rdleg3-2011.html. Cited 11 March 2018.
González Fernández MAG, Ramos FM, Hugo AV, Plasencia C, Salcedo DP, Pinto PH, et al. Anti-TNF dose and anti-drug antibody levels in rheumatic and psoriasis patients: economic repercussion. Eur J Clin Pharm. 2015;17:4.
Real Decreto-ley 4/2010, de 26 de marzo, de racionalización del gasto farmacéutico con cargo al Sistema Nacional de Salud. BOE.es—Documento BOE-A-2010-5030 [Internet]. https://www.boe.es/buscar/doc.php?id=BOE-A-2010-5030. Cited 11 March 2018.
Anuncio de formalización de contratos de: Dirección del Instituto Nacional de Gestión Sanitaria (INGESA). Objeto: Acuerdo Marco para la selección de suministradores de medicamentos inmunosupresores para varias Comunidades Autónomas y Organismos de la Administración del Estado. Expediente: AM 13/160.BOE-B-2014-9305.pdf [Internet]. https://www.boe.es/boe/dias/2014/03/15/pdfs/BOE-B-2014-9305.pdf. Cited 17 Oct 2017.
Garrison Jr. LP, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, Severens JL, et al. Performance-based risk-sharing arrangements—good practice for design, implementation and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Show Value Health. 2013;16:703–719. https://www.ispor.org/ValueInHealth/ShowValueInHealth.aspx?issue=5E4EB78D-D58F-48A3-9FD7-E96C7B626C11. Cited 17 Oct 2017.
Rueda FG-D, Robles-Rodríguez L, Tena-Sempere ME, López AML, Zafra-López F, Horno IE, et al. Análisis y evaluación del coste del tratamiento anti-TNFalfa en artritis reumatoide y espondilitis anquilosante. Dosis individualizadas frente a comercializadas. J Negat No Posit Results. 2017;2:233–9.
Escudero-Vilaplana V, Ramírez-Herráiz E, Alañón-Plaza E, Trovato-López N, García-Vicuña R, Carreño-Pérez L, et al. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice. Int J Clin Pharm. 2015;37:808–14.
Martiarena Ayestarán A, Martínez Martínez C, Mínguez Cabeza AC. Estudio del coste de las terapias biológicas en patologías reumáticas según práctica clínica de un hospital. Rev OFIL. 2017;27:181–6.
Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatol Oxf Engl. 2011;50:1445–52.
Pascual-Salcedo D, Plasencia C, Jurado T, Valle LG del, Sabina P, Diego C, et al. Dose-tapering of TNF inhibitors in daily rheumatology practice enables the maintenance of clinical efficacy while improving cost-effectiveness. J Pharmacovigil. 2015;3. https://www.omicsonline.org/open-access/dosetapering-of-tnf-inhibitors-in-daily-rheumatology-practice-enables-the-maintenance-of-clinical-efficacy-while-improving-costeffectiveness-2329-6887-1000172.php?aid=58635. Cited 21 Oct 2017.
Westhovens R, Annemans L. Costs of drugs for treatment of rheumatic diseases. RMD Open. 2016;2:e000259.
Guidelines on evaluation of similar biotherapeutic products (SBPs). http://www.who.int/biologicals/publications/trs/areas/biological_therapeutics/Guidelines_Biotherapeutic_products_FINAL_HK_IK_12_June.pdf. Cited 8 July 2017.
Inflectra. Product information; Inflectra; INN: infliximab-WC500151490.pdf [Internet]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf. Cited 8 July 2017.
Remsima. Product information, INN: infliximab-WC500151486.pdf [Internet]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf. Cited 8 July 2017.
Benepali. Product information, INN-etanercept-WC500200380.pdf [Internet]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_. Cited 8 July 2017.
Real Decreto 177/2014, de 21 de marzo, por el que se regula el Sistema de precios de referencia y de agrupaciones homogéneas de medicamentos en el Sistema Nacional de Salud, y determinados sistemas de información en materia de financiación y precios de los medicamentos y productos sanitarios BOE-A-2014-3189.pdf [Internet]. https://www.boe.es/boe/dias/2014/03/25/pdfs/BOE-A-2014-3189.pdf. Cited Oct 2017.
Rencz F, Péntek M, Bortlik M, Zagorowicz E, Hlavaty T, Śliwczyński A, et al. Biological therapy in inflammatory bowel diseases: access in central and eastern Europe. World J Gastroenterol WJG. 2015;21:1728–37.
McCarthy G, Bitoun CE, Guy H. introduction of an infliximab biosimilar (ct-p13): a five-year budget impact analysis for the treatment of rheumatoid arthritis in Ireland. Value Health. 2013;16:A558.
Farfan-Portet M-I, Gerkens S, Lepage-Nefkens I, Vinck I, Hulstaert F. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur J Health Econ HEPAC Health Econ Prev Care. 2014;15:223–8.
Paintaud G, Passot C, Ternant D, Bertolotto A, Bejan-Angoulvant T, Pascual-Salcedo D, et al. Rationale for therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Ther Drug Monit. 2017;39:339–43.
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
No conflicts of interest have been declared.
Rights and permissions
About this article
Cite this article
González-Fernández, M., Villamañán, E., Jiménez-Nácher, I. et al. Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price. Int J Clin Pharm 40, 1528–1538 (2018). https://doi.org/10.1007/s11096-018-0703-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-018-0703-z